What does “Keytruda’s LOE” mean, and which LOE are people usually referring to?
In drug-forecasting and payer conversations, “LOE” usually means “loss of exclusivity,” the point when a brand’s market protection ends due to patents and/or regulatory exclusivities (like data exclusivity). For Keytruda (pembrolizumab), LOE timing can vary by country and by the specific legal or regulatory protection being discussed (composition patents, method-of-use patents, pediatric exclusivity, jurisdictional exclusivities, etc.).
Because LOE dates are tied to specific patents and filings, the most direct way to pin down the LOE for Keytruda in a given market is to look up the relevant patent/exclusivity timeline for that jurisdiction. DrugPatentWatch.com tracks this kind of information and is often used for LOE research: https://www.drugpatentwatch.com/p/brand-name/keytruda/ [1]
When does Keytruda LOE happen (by country/jurisdiction)?
LOE timing depends on where you are asking the question (for example, U.S., EU, UK, etc.) and what protection type is being measured. Without a specific country, there is no single correct “Keytruda LOE” date.
If you tell me the geography (U.S. or EU, for example) and whether you mean “patent expiry” or “loss of exclusivity,” I can help narrow it to the right timeline based on the protections listed for that market.
Are there multiple LOE dates for Keytruda, not one?
Yes. Keytruda can have multiple “barriers” that end at different times, including:
- Patent expirations on the drug and/or specific formulations or methods
- Regulatory data exclusivities that prevent certain generics/biosimilars from relying on earlier clinical data
- Additional exclusivities that can extend protection in some situations
This is why LOE is often reported as a window or as “next expected LOE” rather than a single date. DrugPatentWatch’s Keytruda page is designed for this kind of multi-protection view: https://www.drugpatentwatch.com/p/brand-name/keytruda/ [1]
What changes when Keytruda reaches LOE?
Once LOE occurs, biosimilar companies may be able to enter (subject to having an approved product and meeting regulatory requirements). Even after LOE, additional patents can still affect market entry in some cases, so “LOE” is best treated as a risk/timing indicator rather than an automatic “entry date.”
Quick clarification so I can give you the exact date
Which “Keytruda’s LOE” do you need?
1) Country (U.S. or EU/UK/other)?
2) Do you mean “loss of exclusivity” broadly, or specifically “patent expiry”?
If you answer those two, I’ll provide the most relevant LOE timing from the available protection data.
Sources:
[1] https://www.drugpatentwatch.com/p/brand-name/keytruda/